CoChat

Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides

Christgau, Stephan, Rosenquist, Christian, Alexandersen, Peter, Bjarnason, Nina Hannover, Ravn, Pernille, Fledelius, Christian, Herling, Christian, Qvist, Per, Christiansen, Claus · 1998 · Clinical Chemistry
Cited by 144

The DOI matches its Crossref record.

Abstract

The Serum CrossLapsTM One Step ELISA is a sandwich assay using two monoclonal antibodies specific for a β-aspartate form of the epitope EKAHDGGR derived from the carboxy-terminal telopeptide region of type I collagen α1-chain. Our objective was to assess the clinical value of the Serum CrossLaps assay for monitoring antiresorptive therapy in osteoporosis treatment. Samples obtained from postmenopausal women treated with different doses of cyclic or continuous hormone replacement therapy (HRT) with an estrogen analog (tibolone) or with a bisphosphonate (ibandronate) were measured in the Serum CrossLaps One Step ELISA at baseline and at various time points during therapy. The corresponding urine samples were measured in the urine CrossLapsTM ELISA and corrected for creatinine excretion. The serum CrossLaps measurements and corresponding urinary CrossLaps measurements were highly correlated (r >0.8 for all studies). The serum and urine CrossLaps measurements showed a significant decrease among the women treated with clinically relevant doses of either of the antiresorptive agents. Furthermore, the annual percentage change in bone mineral density (BMD) correlated with the measured changes in CrossLaps concentration. The serum CrossLaps assay showed a specificity of 83–100% and a sensitivity of 59–83% for assessing BMD changes. The corresponding values for the creatinine-corrected urinary measurements were 83–92% specificity and 68–79% sensitivity. We conclude that performance of the convenient Serum CrossLaps One Step ELISA is at least equivalent to that of the urine text for follow up of antiresorptive treatment in osteoporosis. Further studies are needed to optimize its use in this and other clinical applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/clinchem/44.11.2290

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 144

Metadata

Authors
Christgau, S., Rosenquist, C., Alexandersen, P., Bjarnason, N. H., Ravn, P., Fledelius, C., Herling, C., Qvist, P., & Christiansen, C.
Venue
Clinical Chemistry
Published
1998-11-01
Volume
44
Issue
11
Pages
2290-2300
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2136069822
Cited by
144
References
0
FWCI
11.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. https://app.cochat.ai/papers/10.1093/clinchem/44.11.2290
The paper
Christgau, S., Rosenquist, C., Alexandersen, P., Bjarnason, N. H., Ravn, P., Fledelius, C., Herling, C., Qvist, P., & Christiansen, C. (1998). Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clinical Chemistry. https://doi.org/10.1093/clinchem/44.11.2290

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.